|September 26, 2013|
|16:43 EDT||ECYT, JNJ||Endocyte says Doxil supply interruption will not affect PROCEED trial|
Endocyte (ECYT) disclosed in a regulatory filing that Janssen Products, a Johnson & Johnson company (JNJ), informed healthcare providers on September 25, of an anticipated interruption of supply of Doxil. Endocyte’s Phase 3 PROCEED trial evaluating vintafolide and etarfolatide in women with platinum resistant ovarian cancer includes Doxil as the control drug. As previously disclosed, Endocyte has purchased a substantial supply of Doxil to support the PROCEED trial. This supply is expected to be sufficient to support patients currently on trial and new enrollment for the next 9-12 months, which would be beyond the interim analysis of the trial. Enrollment in the trial will continue uninterrupted in the meantime. Endocyte will continue to collaborate with Janssen to ensure ongoing supply of Doxil in order to complete the PROCEED trial.
News For ECYT;JNJ From The Last 14 Days
Check below for free stories on ECYT;JNJ the last two weeks.
|December 9, 2013|
|19:06 EDT||JNJ||J&J's Janssen reports ibrutinib met primary endpoint of safety|
Janssen announced data from a study published in The Lancet Oncology, evaluating the safety and activity of ibrutinib as a single-agent therapy in patients over the age of 65 with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. The study met its primary endpoint of safety, with data demonstrating treatment with ibrutinib as an initial therapy was associated with adverse events that were predominantly Grade 1 or 2 in nature. Efficacy data were also collected and showed that 71% of patients treated with ibrutinib achieved an objective response. Although estimates of progression-free survival and overall survival were not reached at the median follow up of 22.1 months, it is estimated that more than 95% of patients would be alive and progression-free at two years.
|07:01 EDT||JNJ||Myriad Genetics announces cancer research collaboration with Janssen|
Subscribe for More Information
|December 8, 2013|
|18:45 EDT||JNJ||J&J's siltuximab improves symptoms in Castleman disease, Bloomberg says |
Subscribe for More Information
|December 5, 2013|
|07:59 EDT||JNJ||Cooper Companies added to Select List at Stifel|
Stifel added Cooper Companies (COO) to its Select List after surveying 36 optometry practices in the U.K. The firm reports that Cooper's new silicone hydrogel daily lens, MyDay, appears to be performing well in the country, and is ranked ahead of J&J's (JNJ) competing TruEye by optometrists there. The firm keeps a $150 price target and Buy rating on Cooper.
|December 4, 2013|
|16:51 EDT||JNJ||Johnson & Johnson unit to pay $1.25M to settle with FDA|
The U.S. Food and Drug Administration has reached a $1.25M settlement of a civil money penalty action against Advanced Sterilization Products, a division of Ethicon, a Johnson & Johnson company, and two of ASP’s executives alleging that ASP manufactured and distributed adulterated and misbranded sterilization monitoring products. The settlement requires ASP to pay $1.2M, company president Bernard Zovighian to pay $30,000, and company VP of quality and regulatory compliance Richard Alberti to pay $20,000. Reference Link
|December 3, 2013|
|08:56 EDT||JNJ||LabCorp announces availability of enhanced HCV GenoSure NS3/4|
Laboratory Corporation (LH) announced the immediate availability of an enhanced version of its HCV GenoSure NS3/4, a drug resistance test that screens for the Q80K polymorphism. Q80K is a naturally occurring polymorphism that develops in certain strains of HCV, making the virus less susceptible to Janssen Therapeutics’ (JNJ) OLYSIO, which was recently approved by the U.S. Food and Drug Administration for the treatment of certain adult patients diagnosed with genotype 1chronic hepatitis C.
|December 2, 2013|
|10:00 EDT||ECYT||On The Fly: Analyst Initiation Summary|
Today's noteworthy initiation include: Arc Logistics (ARCX) initiated with an Overweight at Barclays... Barracuda Networks (CUDA) initiated with an Overweight at JPMorgan... Blue Capital (BCRH) initiated with an Equal Weight at Barclays... CST Brands (CST) initiated with a Buy at Mizuho... EXCO Resources (XCO) reinstated with a Sell at Goldman... Endocyte (ECYT) initiated with an Overweight at Piper Jaffray... Federated National (FNHC) initiated with an Outperform at Raymond James... Gaming and Leisure Properties (GLPI) initiated with an Outperform at Wells Fargo... LGI Homes (LGIH) initiated with a Buy at Deutsche Bank... Mavenir Systems (MVNR) initiated with a Buy at BofA/Merrill... Millennial Media (MM) initiated with an Overweight at Evercore... Norcraft (NCFT) initiated with an Outperform at RBC Capital... Rocket Fuel (FUEL) initiated with an Underweight at Evercore... Sophiris Bio (SPHS) initiated with a Neutral at Citigroup... Tableau Software (DATA) initiated with a Sector Perform at RBC Capital... Tetra Technologies (TTI) initiated with a Market Perform at Cowen... Twitter (TWTR) initiated with an Underperform at BofA/Merrill... VMware (VMW) initiated with an Overweight at Atlantic Equities... Wix.com (WIX) initiated with an Outperform at RBC Capital... Sandstorm Gold (SAND) initiated with an Outperform at Raymond James... Royal Gold (RGLD) initiated with a Strong Buy at Raymond James... Franco-Nevada (FNV) initiated with a Market Perform at Raymond James... ServiceSource (SREV) initiated with a Buy at Dougherty... MPLX (MPLX)initiated with a Sector Perform at Howard Weil... Holly Energy (HEP) initiated with a Sector Perform at Howard Weil... CAS Medical (CASM) initiated with an Outperform at Northland Securities... Tesoro Logistics (TLLP) initiated with an Outperform at Howard Weil... Delek Logistics (DKL) initiated with an Outperform at Howard Weil... Stonegate Mortgage (SGM) initiated with a Buy at BofA/Merrill... Ring Energy (REI) initiated with a Buy at Ladenburg... ADMA Biologics (ADMA) initiated with a Buy at Maxim... Karyopharm (KPTI) initiated with an Outperform at JMP Securities.
|05:44 EDT||ECYT||Endocyte initiated with an Overweight at Piper Jaffray|
Subscribe for More Information
|November 27, 2013|
|13:21 EDT||JNJ||J&J may pay $1B in medical costs under hip settlement, Bloomberg says|
Johnson & Johnson may have to pay up to $1B to insurers who covered the medical costs of removing its recalled hip implants under the settlement announced previously, says Bloomberg. Reference Link